Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial

Autor: Søren Cold, Marianne Ewertz, Hanne Melgaard Nielsen, Julia Kenholm, Dorte Carlsen, Malgorzata K Tuxen, Ann Knoop, Eva Balslev, Troels Bechmann, Erik Jakobsen, Hella Danø, Michael Andersson, Dorte Nielsen, Inger Højris, Henning T. Mouridsen, Bent Ejlertsen, Else Maae, Peter Michael Vestlev, Maj-Britt Jensen

Publikováno v: Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer : DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494

Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-lab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d31fe2d3f63dba4f1402d624553e76
https://doi.org/10.1200/jco.2017.72.3494

Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer

Autor: Flemming Brandt Sørensen, Karina Dahl Steffensen, Ivan Brandslund, Else Maae, Anders Jakobsen, Dorte Aalund Olsen, Erik Jakobsen

Publikováno v: Maae, E, Olsen, D A, Steffensen, K D, Jakobsen, E H, Brandslund, I, Sørensen, F B & Jakobsen, A 2012, ' Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer ', Breast Cancer Research and Treatment, bind 133, nr. 1, s. 257-265 . https://doi.org/10.1007/s10549-012-1957-0
University of Southern Denmark
Maae, E, Olsen, D A, Dahl Steffensen, K, Jakobsen, E H, Brandslund, I, Sørensen, F B & Jakobsen, A 2012, ' Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer ' .
Maae, E, Olsen, D A, Dahl Steffensen, K, Jakobsen, E H, Brandslund, I, Sørensen, F B & Jakobsen, A 2012, ' Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer ', DSKO, Nyborg, Denmark, 22/04/2012-22/04/2012 .
Maae, E, Olsen, D A, Steffensen, K D, Jakobsen, E H, Brandslund, I, Sørensen, F B & Jakobsen, A 2012, ' Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer ', Breast Cancer Research and Treatment, vol. 133, no. 1, pp. 257-265 . https://doi.org/10.1007/s10549-012-1957-0

Background: Placenta growth factor (PlGF) and vascular endothelial growth factor A (VEGF-A) are angiogenic growth factors interacting competitively with the same receptors. VEGF-A is essential in both normal and pathologic conditions, but the functio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::739e77d4983650b9d38313ffd970e467
https://pure.au.dk/portal/da/publications/prognostic-impact-of-placenta-growth-factor-and-vascular-endothelial-growth-factor-a-in-patients-with-breast-cancer(d2b48d94-b7b8-45a7-9232-8ba0e0512e32).html

Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast

Autor: Else Maae, Karina Dahl Steffensen, Erik Jakobsen, A. Jakobsen, Flemming Brandt Sørensen, Martin Nielsen

Publikováno v: Aarhus University
Maae, E, Nielsen, M, Dahl Steffensen, K, Jakobsen, E H, Jakobsen, A & Sørensen, F B 2011, ' Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast ' Journal of Histochemistry and Cytochemistry, bind 59, nr. 8, s. 750-760 .
University of Southern Denmark
Maae, E, Nielsen, M, Dahl Steffensen, K, Jakobsen, E H, Jakobsen, A & Sørensen, F B 2012, ' Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast ' .
Maae, E, Nielsen, M, Dahl Steffensen, K, Jakobsen, E H, Jakobsen, A & Sørensen, F B 2011, ' Estimation of Immunohistochemical Expression of VEGF in Ductal Carcinomas of the Breast ', Journal of Histochemistry and Cytochemistry, vol. 59, no. 8, pp. 750-760 .

Introduction: Vascular endothelial growth factor A (VEGF-A) is a very important growth factor in angiogenesis and holds the potential as both a predictive marker for anti-angiogenic cancer treatment and as a prognostic variable. Consequently, reliabl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c67f928973152afc04c791bc0adf506
https://pubmed.ncbi.nlm.nih.gov/21606203

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

Autor: Ejlertsen B; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Tuxen MK; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Jakobsen EH; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Jensen MB; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Knoop AS; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Højris I; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Ewertz M; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Balslev E; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Danø H; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Vestlev PM; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Kenholm J; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Nielsen DL; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Bechmann T; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Andersson M; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Cold S; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Nielsen HM; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Maae E; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Carlsen D; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark., Mouridsen HT; Bent Ejlertsen, Maj-Britt Jensen, and Henning T. Mouridsen, Danish Breast Cancer Cooperative Group, Rigshospitalet; Ann Soegaard Knoop and Michael Andersson, Rigshospitalet; Malgorzata K. Tuxen, Eva Balslev, Dorte L. Nielsen, and Dorte Carlsen, Herlev and Gentofte Hospital, Copenhagen; Erik Hugger Jakobsen, Troels Bechmann, and Else Maae, Lillebaelt Hospital, Vejle; Inger Højris and Hanne Melgaard Nielsen, Aarhus University Hospital, Aarhus; Marianne Ewertz, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark; Søren Cold, Odense University Hospital, Odense; Hella Danø, Nordsjaellands Hospital, Hilleroed; Peter Michael Vestlev, Zealand University Hospital, Roskilde; and Julia Kenholm, Regional Hospital West Jutland, Herning, Denmark.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Aug 10; Vol. 35 (23), pp. 2639-2646. Date of Electronic Publication: 2017 Jun 29.